Filtered By:
Cancer: Breast Cancer
This page shows you your search results in order of date. This is page number 16.
Order by Relevance | Date
Total 677 results found since Jan 2013.
Individual Benefits and Risks of Intravaginal Estrogen and Systemic Testosterone in the Management of Women in the Menopause, With a Discussion of Any Associated Risks for Cancer Development
Cancer J. 2022 May-Jun 01;28(3):196-203. doi: 10.1097/PPO.0000000000000598.ABSTRACTSeveral formulations of intravaginal oestrogen are available for the treatment of genitourinary syndrome of menopause (GSM). These are safe and effective treatments for the symptoms of GSM. Licensed doses of intravaginal oestrogen do not elevate systemic estradiol levels above the normal postmenopausal range with long term use and there is no evidence of an increased risk of coronary heart disease, stroke, thromboembolism, colorectal cancer, endometrial cancer, breast cancer or breast cancer recurrence with their use. This should reassure bo...
Source: Cancer Journal - May 20, 2022 Category: Cancer & Oncology Authors: Abbie J Laing Louise Newson James A Simon Source Type: research
Menopausal Hormone Replacement Therapy and Reduction of All-Cause Mortality and Cardiovascular Disease: It Is About Time and Timing
Cancer J. 2022 May-Jun 01;28(3):208-223. doi: 10.1097/PPO.0000000000000591.ABSTRACTThe totality of evidence indicates menopausal hormone replacement therapy (HRT) effects are determined by timing of initiation according to age and/or time since menopause, underlying health of target tissue, and duration of therapy. Initiated in women at younger than 60 years and/or at or near menopause, HRT significantly reduces all-cause mortality and cardiovascular disease (CVD), whereas other primary CVD prevention therapies such as lipid-lowering fail to do so. The magnitude and type of HRT-associated risks, including breast cancer, st...
Source: Cancer Journal - May 20, 2022 Category: Cancer & Oncology Authors: Howard N Hodis Wendy J Mack Source Type: research
Individual Benefits and Risks of Intravaginal Estrogen and Systemic Testosterone in the Management of Women in the Menopause, With a Discussion of Any Associated Risks for Cancer Development
Cancer J. 2022 May-Jun 01;28(3):196-203. doi: 10.1097/PPO.0000000000000598.ABSTRACTSeveral formulations of intravaginal oestrogen are available for the treatment of genitourinary syndrome of menopause (GSM). These are safe and effective treatments for the symptoms of GSM. Licensed doses of intravaginal oestrogen do not elevate systemic estradiol levels above the normal postmenopausal range with long term use and there is no evidence of an increased risk of coronary heart disease, stroke, thromboembolism, colorectal cancer, endometrial cancer, breast cancer or breast cancer recurrence with their use. This should reassure bo...
Source: Cancer Journal - May 20, 2022 Category: Cancer & Oncology Authors: Abbie J Laing Louise Newson James A Simon Source Type: research
Menopausal Hormone Replacement Therapy and Reduction of All-Cause Mortality and Cardiovascular Disease: It Is About Time and Timing
The totality of evidence indicates menopausal hormone replacement therapy (HRT) effects are determined by timing of initiation according to age and/or time since menopause, underlying health of target tissue, and duration of therapy. Initiated in women at younger than 60 years and/or at or near menopause, HRT significantly reduces all-cause mortality and cardiovascular disease (CVD), whereas other primary CVD prevention therapies such as lipid-lowering fail to do so. The magnitude and type of HRT-associated risks, including breast cancer, stroke, and venous thromboembolism, are rare (
Source: The Cancer Journal - May 1, 2022 Category: Cancer & Oncology Tags: Review Articles Source Type: research
Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study
CONCLUSION: Women with BC had increased incidence of CVD events, CVD-related mortality, and all-cause mortality compared with women without BC, and risks varied according to the history of cancer treatment received. Studies are needed to determine how women who received BC treatment should be cared for to improve cardiovascular outcomes.PMID:35385342 | DOI:10.1200/JCO.21.01736
Source: Clinical Genitourinary Cancer - April 6, 2022 Category: Cancer & Oncology Authors: Heather Greenlee Carlos Iribarren Jamal S Rana Richard Cheng Mai Nguyen-Huynh Eileen Rillamas-Sun Zaixing Shi Cecile A Laurent Valerie S Lee Janise M Roh Margarita Santiago-Torres Hanjie Shen Dawn L Hershman Lawrence H Kushi Romain Neugebauer Marilyn L Kw Source Type: research
New ERLEADA ® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
SAN FRANCISCO, Feb. 14, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA® (apalutamide) results in high rates of rapid and deep prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC). In a separate post-hoc analysis of the registrational Phase 3 SPARTAN and TITAN studies, rapid and deep PSA responses with ERLEADA® were associated with improvement in patient-reported outcomes (PROs) related to quality of life, physical wellbeing, pain, and fatigue intensity. The...
Source: Johnson and Johnson - February 14, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Molecular and pharmacological aspects of piperine as a potential molecule for disease prevention and management: evidence from clinical trials
CONCLUSION: Based on the current evidence, piperine can be the potential molecule for treatment of disease, and its significance of this molecule in the clinic is discussed.PMID:35127957 | PMC:PMC8796742 | DOI:10.1186/s43088-022-00196-1
Source: Appl Human Sci - February 7, 2022 Category: Physiology Authors: Amit Kumar Tripathi Anup Kumar Ray Sunil Kumar Mishra Source Type: research
